Emma Wingert, PA
Physician Assistant · Wichita, KSNPI 1235874728
Payments from drug & device makers
Across 510 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Medtronic$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Dexcom, Inc.$811
- Insulet Corporation$439
- plus $4K from 32 others
What the payments were for
- Travel & lodging$2,09021%
- Food & beverage$7,93678%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 5 | $1,584 |
| Medtronic | 19 | $1,485 |
| Lilly USA, LLC | 70 | $1,127 |
| Novo Nordisk | 87 | $1,074 |
| Dexcom, Inc. | 58 | $811 |
| Insulet Corporation | 49 | $439 |
| Corcept Therapeutics | 33 | $424 |
| Bayer | 22 | $393 |
| Xeris Pharmaceuticals, Inc. | 23 | $344 |
| AbbVie | 20 | $306 |
| Amgen | 19 | $298 |
| Recordati_rare_diseases_inc. | 11 | $227 |
| AstraZeneca(2 entities) | 11 | $177 |
| Novartis | 11 | $168 |
| Boehringer Ingelheim | 11 | $166 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Astellas Pharma US Inc | 7 | $116 |
| Amneal Pharmaceuticals LLC | 6 | $104 |
| Ascensia Diabetes Care US Inc. | 5 | $94 |
| Aimmune Therapeutics, Inc. | 4 | $89 |
| Neurocrine Biosciences, Inc. | 4 | $89 |
| Radius Health, Inc. | 4 | $71 |
| Abbott | 3 | $57 |
| Chiesi USA, Inc. | 3 | $50 |
| IBSA Pharma Inc. | 3 | $47 |
| EUSA Pharma (US) LLC | 2 | $33 |
| BETA Bionics, Inc. | 2 | $30 |
| Nevro Corp. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Globus Medical | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,470
- MINIMED 780G$1,037
- MOUNJARO$125
- Kerendia$108
How this compares
$10,135 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $303,685 |
| MounjaroTirzepatide | 172 | $203,596 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $110,294 |
| JardianceEmpagliflozin | 57 | $85,146 |
| TrulicityDulaglutide | 72 | $83,393 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $66,254 |
| FarxigaDapagliflozin Propanediol | 61 | $63,385 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $62,566 |
| JanuviaSitagliptin Phosphate | 45 | $57,113 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $37,847 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $28,824 |
| Novolog FlexpenInsulin Aspart | 52 | $26,335 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $20,671 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $18,771 |
| Humalog Kwikpen U-100Insulin Lispro | 48 | $18,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,074 | $342,386241 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,127 | $286,989244 claims |
| Boehringer IngelheimJardiance, Tradjenta | $166 | $99,47771 claims |
| MerckJanuvia, Janumet | $12 | $72,91471 claims |
| AstraZenecaFarxiga | $177 | $63,38561 claims |
| AbbVieSynthroid | $306 | $5,51362 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $104 | $2,189254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Wichita
- Sierra FergusonWichita$25K
- Ashton YoungersWichita$14K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Jenny MartensWichita$13K
- Shanna SudermanWichita$13K
- Megan HolickWichita$12K
- Colleen YoungWichita$11K
- Kathleen Dang-PhamWichita$11K
- Trinh HoangWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.